American journal of obstetrics and gynecology · 2007
Betamethasone vs dexamethasone for the prevention of morbidity in very-low-birthweight neonates.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Feldman Deborah M, Carbone Jeannine, Belden Laura, Borgida Adam F, Herson Victor
Аннотация
OBJECTIVE: The purpose of this study was to compare neonatal outcomes in very-low-birthweight infants who were exposed to antenatal betamethasone vs dexamethasone.
STUDY DESIGN: We reviewed all inborn very-low-birthweight infants from January 1997 through February 2006. Maternal medical records were reviewed to determine the type of antenatal steroids that each patient received; neonatal outcomes were compared using chi-square and Student t tests.
RESULTS: There were 334 very-low-birthweight infants who met the criteria for evaluation: 186 infants received betamethasone, and 148 infants received dexamethasone. There were no differences in race, gestational age at delivery, or mean birthweight between the 2 groups. There were significantly lower rates of respiratory distress syndrome and bronchopulmonary dysplasia in the betamethasone group, compared with the dexamethasone group. Other neonatal outcomes were similar in both groups.
CONCLUSION: Antenatal betamethasone was associated with a significantly lower rate of pulmonary complications caused by prematurity, when compared with dexamethasone.
STUDY DESIGN: We reviewed all inborn very-low-birthweight infants from January 1997 through February 2006. Maternal medical records were reviewed to determine the type of antenatal steroids that each patient received; neonatal outcomes were compared using chi-square and Student t tests.
RESULTS: There were 334 very-low-birthweight infants who met the criteria for evaluation: 186 infants received betamethasone, and 148 infants received dexamethasone. There were no differences in race, gestational age at delivery, or mean birthweight between the 2 groups. There were significantly lower rates of respiratory distress syndrome and bronchopulmonary dysplasia in the betamethasone group, compared with the dexamethasone group. Other neonatal outcomes were similar in both groups.
CONCLUSION: Antenatal betamethasone was associated with a significantly lower rate of pulmonary complications caused by prematurity, when compared with dexamethasone.